Valuation: Wockhardt Limited

Capitalization 191B 1.98B 1.71B 1.56B 1.48B 2.73B 2.78B 18.6B 7.26B 90.38B 7.44B 7.28B 315B P/E ratio 2024
-18.2x
P/E ratio 2025 -472x
Enterprise value 205B 2.13B 1.84B 1.68B 1.59B 2.94B 2.99B 19.99B 7.81B 97.16B 7.99B 7.82B 339B EV / Sales 2024
3.82x
EV / Sales 2025 8.1x
Free-Float
48.98%
Yield 2024 *
-
Yield 2025 -
1 day-0.75%
1 week+2.22%
Current month+14.63%
1 month+13.99%
3 months+15.79%
6 months+20.73%
Current year+10.62%
1 week 1,510.1
Extreme 1510.1
1,655.9
1 month 1,382
Extreme 1382
1,778
Current year 1,086.7
Extreme 1086.7
1,778
1 year 1,086.7
Extreme 1086.7
1,868.8
3 years 167
Extreme 167
1,868.8
5 years 145.15
Extreme 145.15
1,868.8
10 years 145.15
Extreme 145.15
1,868.8
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5d. change 1-year change 3-years change Capi.($)
-0.75%+2.22%+20.77%+842.72% 2.71B
+0.59%+3.64%+10.74%+104.28% 46.71B
+2.50%+4.89%+77.26%+137.55% 37.81B
+0.17%+5.60%-3.61%+53.00% 11.7B
-0.42%+10.35%+17.34%+109.51% 10.84B
0.00%+0.78%+38.17%+126.43% 9.06B
-1.55%-4.75%+16.34%+47.61% 7.21B
+0.80%-4.19%+62.74%-5.90% 7.18B
+0.59%+5.07%+66.62%+283.31% 6.95B
+0.95%-3.59%-14.18%+3.86% 5.89B
Average +0.45%+2.54%+29.22%+170.24% 14.61B
Weighted average by Cap. +0.92%+2.87%+33.67%+120.51%

Financials

2024 2025
Net sales 28.3B 294M 253M 232M 219M 405M 412M 2.75B 1.08B 13.39B 1.1B 1.08B 46.73B 30.35B 315M 272M 248M 235M 434M 442M 2.95B 1.15B 14.36B 1.18B 1.16B 50.12B
Net income -4.63B -48.03M -41.45M -37.9M -35.83M -66.21M -67.39M -451M -176M -2.19B -180M -176M -7.65B -470M -4.88M -4.21M -3.85M -3.64M -6.72M -6.84M -45.75M -17.87M -222M -18.3M -17.91M -776M
Net Debt 18.33B 190M 164M 150M 142M 262M 267M 1.78B 697M 8.67B 714M 698M 30.27B 14.33B 149M 128M 117M 111M 205M 209M 1.39B 545M 6.78B 558M 546M 23.66B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,296
Date Price Change Volume
26-05-21 1,599.80 -0.75% 761,546
26-05-20 1,611.90 -0.51% 1,252,630
26-05-19 1,620.20 +3.10% 1,406,803
26-05-18 1,571.50 +1.66% 1,529,448
26-05-15 1,545.90 -0.08% 1,029,542
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Equities
  3. WOCKPHARMA Stock